journal
https://read.qxmd.com/read/38646879/evaluation-of-safety-outcomes-with-transitioning-obinutuzumab-from-standard-rate-to-short-duration-infusion-in-patients-with-chronic-lymphocytic-leukemia
#21
JOURNAL ARTICLE
Caroline Fleck, Allison Karabinos, Allene Cook, Donald C Moore, Ryan Jacobs
No abstract text is available yet for this article.
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38646877/evaluating-targeted-therapies-in-older-patients-with-tp53-mutated-aml
#22
REVIEW
Jean M G Sabile, Ronan Swords, Jeffrey W Tyner
Mutation of thetumor suppressor gene, TP53 ( tumor protein 53 ), occurs in up to 15% of all patients with acute myeloid leukemia (AML) and is enriched within specific clinical subsets, most notably in older adults, and including secondary AML cases arising from preceding myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), patients exposed to prior DNA-damaging, cytotoxic therapies. In all cases, these tumors have remained difficult to effectively treat with conventional therapeutic regimens. Newer approaches fortreatmentof TP53- mutated AML have shifted to interventions that maymodulate TP53 function, target downstream molecular vulnerabilities, target non-p53 dependent molecular pathways, and/or elicit immunogenic responses...
April 22, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38638066/light-chain-restricted-russell-body-oral-mucositis-an-immunohistochemical-study-and-literature-review
#23
JOURNAL ARTICLE
Luana Stefanie Silvino Gonçalves, Karina Helen Martins, Magdalena Raquel Torres Reyes, Isabella Silva Catananti, Fernando Chahud, Jorge Esquiche León
No abstract text is available yet for this article.
April 18, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38635491/management-of-relapsed-refractory-mantle-cell-lymphoma
#24
REVIEW
Musa Alzahrani, Diego Villa
In this review we summarize the current evidence describing the management of patients with relapsed/refractory MCL and outline the various novel therapeutics that have been developed over the past two decades. We also describe how overall response rates, complete response rates, duration of responses, and life expectancy have dramatically increased with the introduction of novel therapies, particularly covalent Bruton Tyrosine Kinase inhibitors (BTKi) and chimeric antigen receptor T-cell (CAR-T) therapy. The most recent emerging options for patients with progressive disease following BTKi or CAR-T, including non-covalent BTKi, antibody-drug conjugates, Bcl-2 inhibitors, and bispecific antibodies, may further improve response rates and outcomes...
April 18, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38635368/high-remission-rates-and-transition-to-allogeneic-transplant-in-older-patients-with-newly-diagnosed-flt-3-mutated-acute-myelogenous-leukemia-with-midostaurin-plus-intensive-chemotherapy
#25
JOURNAL ARTICLE
Jose Tinajero, Dat Ngo, Jianying Zhang, Ni-Chun Tsai, Ahmed Aribi, Ibrahim Aldoss, Vaibhav Agrawal, Shukaib Arslan, Idoroenyi Amanam, Hoda Pourhassan, Karamjeet Sandhu, Monzr Al-Malki, Vinod Pullarkat, Pamela Becker, Ryotaro Nakamura, Anthony Stein, Guido Marcucci, Andrew Artz, Paul Koller, Amandeep Salhotra
No abstract text is available yet for this article.
April 18, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38629176/flotetuzumab-as-a-salvage-immunotherapy-in-advanced-cd123-positive-hematological-malignancies-a-phase-1-pilot-study
#26
JOURNAL ARTICLE
Ibrahim Aldoss, Jianying Zhang, Marjorie Robbins, Joo Song, Monzr M Al Malki, Salman Otoukesh, Karamjeet Sandhu, Vaibhav Agrawal, Alex F Herrera, Leslie L Popplewell, Lucy Ghoda, Anthony Stein, Guido Marcucci, Stephen Forman, Vinod Pullarkat
CD123 "expression" is common in hematological malignancies, including acute lymphoblastic leukemia (ALL). Flotetuzumab is a novel, investigational CD3/CD123 DART®. We conducted a phase 1 study evaluating safety and efficacy of flotetuzumab in relapsed/refractory ALL (Cohort A) and other advanced CD123-positive hematological malignancies (excluding myeloid malignancies) (cohort B). Thirteen patients (9 in Cohort A and 4 in Cohort B) were treated at dose level 1 (500 ng/kg/day) before early closure due to discontinuation of drug development by sponsor...
April 17, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38626450/covid-19-antibody-titers-after-tixagevimab-cilgavimab-injection-in-patients-with-hematologic-diseases-a-single-center-prospective-study
#27
JOURNAL ARTICLE
Naokazu Nakamura, Hiroko Tsunemine, Ryo Ikunari, Tomomi Sakai, Nobuyoshi Arima
Knowledge of the SARS-CoV-2 antibody titers induced by tixagevimab-cilgavimab in patients with hematologic diseases remains insufficient. Here, we performed a single-center, prospective study to reveal the changes in antibody titer after administration of tixagevimab-cilgavimab in 78 patients with hematologic diseases. The median peak titer was 155.4 U/mL, and the median AUC was 46556 days·U/mL. First, we compared several characteristics between patients with low titers (peak titer ≤ 155...
April 16, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38625039/prevalence-of-geriatric-impairments-and-frailty-categorization-among-real-world-patients-with-multiple-myeloma-a-prospective-cohort-study-mfrail
#28
JOURNAL ARTICLE
Imran Haider, Darryl P Leong, Martha Louzada, Arleigh McCurdy, Gregory R Pond, Ruthanne Cameron, Mohammed Aljama, Alissa Visram, Tanya M Wildes, Hira Mian
There is limited knowledge regarding the prevalence of geriatric impairments and frailty among patients with multiple myeloma (MM) in a real-world setting. This study evaluated the distribution of frailty profiles among 116 patients with newly diagnosed or relapsed MM, using four common frailty scales. The proportion of patients classified as frail varied significantly, ranging from 15.5% to 56.9%, due to differences in how frailty was operationalized between each frailty measure. Functional, cognitive, and mobility impairments were common overall and irrespective of performance status...
April 16, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38619488/the-impact-of-race-and-ethnicity-on-diffuse-large-b-cell-lymphoma-outcomes-within-the-veterans-health-administration-vha
#29
JOURNAL ARTICLE
Andrew Ta, Supreet Kaur, Michael Mader, Kathleen Franklin, Madison Williams, Ryan Williams, Jean-Pierre Blaize, Amna Naqvi, Snegha Ananth, Michael Song, Brian Oliver Warnecke, Abhishek Pandya, Lakene Raissa Djoufack Djoumessi, Phillip Nazarewicz, Manuel Espinoza-Gutarra, Kana Tai Lucero, Jennifer Whitehead, Alaq Al-Abayechi, Lauren Boyle, Sophia Lee, Gabriel Roman Souza, Esteban Toro Velez, Ian Mines, Zohra Nooruddin
We performed a retrospective chart review of 6266 randomly selected DLBCL patients treated in the VHA nationwide between 1/1/2011 and 12/31/2021. The 3178 patients who met inclusion criteria were predominantly male (97%) and white (75%). Median age of diagnosis for Black patients was 63 years vs 69 years for the entire cohort ( p  < 0.001). However, patients in each race/ethnicity subgroup presented with similar rates of stage I/II and III/IV disease, IPI score, cell of origin and HIT status...
April 15, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38619476/b-cell-receptor-signaling-proteins-as-biomarkers-for-progression-of-cll-requiring-first-line-therapy
#30
REVIEW
Mischa Y L Vervoordeldonk, Paul J Hengeveld, Mark-David Levin, Anton W Langerak
The molecular landscape of chronic lymphocytic leukemia (CLL) has been extensively characterized, and various potent prognostic biomarkers were discovered. The genetic composition of the B-cell receptor (BCR) immunoglobulin (IG) was shown to be especially powerful for discerning indolent from aggressive disease at diagnosis. Classification based on the IG heavy chain variable gene (IGHV) somatic hypermutation status is routinely applied. Additionally, BCR IGH stereotypy has been implicated to improve risk stratification, through characterization of subsets with consistent clinical profiles...
April 15, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38608254/two-recurrent-types-of-igh-5-bcl2-breakpoints-representing-cytogenetic-ins-14-18-q32-q21q21-and-t-14-18-q32-q21-mediated-by-the-vdj-and-class-switch-recombination-processes-respectively
#31
JOURNAL ARTICLE
Fumiyo Maekawa, Masahiko Hayashida, Kayo Takeoka, Katsuhiro Fukutsuka, Miho Nakagawa, Takashi Akasaka, Shinichi Sakamoto, Shinji Sumiyoshi, Yoichiro Kobashi, Hitoshi Ohno
We describe two types of IGH :: BCL2 breakpoints involving the 5' region of BCL2 (5' BCL2 ). One was ins(14;18)(q32;q21q21) observed in 2 follicular lymphoma (FL) cases, in which IGH was cleaved at 3' of IGHD and 5' of IGHJ and BCL2 was cleaved at 5' BCL2 and downstream regions, and a 281- or 201-kilobase pair fragment containing the BCL2 protein-coding sequences was invertedly inserted into IGH . In another type observed in 2 FL and 2 chronic lymphocytic leukemia (CLL) cases, breakage and reunion occurred within the switch region associated with IGHM (Sµ) and 5' BCL2 , creating IGH Sµ::5' BCL2 fusion sequences on der(18)t(14;18)(q32;q21)...
April 12, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38608253/successful-treatment-with-cladribine-in-a-patient-with-rosai-dorfman-disease-complicated-by-severe-prolonged-marrow-aplasia
#32
JOURNAL ARTICLE
Tadeusz Robak, Marcin Braun, Anna Guminska, Elżbieta Iskierka-Jażdżewska, Paweł Robak
No abstract text is available yet for this article.
April 12, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38606813/correction
#33
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 12, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38600883/the-mechanism-of-action-pharmacological-characteristics-and-clinical-utility-of-the-amyloid-depleter-birtamimab-for-the-potential-treatment-of-al-amyloidosis
#34
REVIEW
Giovanni Palladini, Michaela Liedtke, Wagner Zago, Phil Dolan, Gene G Kinney, Morie A Gertz
Amyloid light chain (AL) amyloidosis is a progressive plasma cell disorder caused by amyloid deposition resulting in organ damage and failure. Current standard-of-care treatments target clonal plasma cells, the source of misfolded light chains (amyloid precursors), yet only half of patients with advanced disease survive ≥6 months. The amyloid depleter birtamimab is an investigational humanized monoclonal antibody that binds misfolded κ and λ light chains with high specificity and was designed to neutralize soluble toxic light chain aggregates and promote phagocytic clearance of deposited amyloid...
April 11, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38598516/safety-and-efficacy-of-parsaclisib-in-combination-with-rituximab-bendamustine%C3%A2-%C3%A2-rituximab-or-ibrutinib-in-patients-with-previously-treated-b-cell-lymphoma-analysis-of-a-phase-1-dose-finding-study-citadel%C3%A2-112
#35
JOURNAL ARTICLE
Juan-Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar, Raul Cordoba, Monica Tani, Peter Langmuir, Erica Rappold, Teng Liu, Armando Lopez-Guillermo
Parsaclisib, a potent and highly selective phosphoinositide 3-kinase δ inhibitor, has shown clinical activity in relapsed/refractory (R/R) B-cell lymphoma. The phase 1 CITADEL-112 (NCT03424122) study assessed safety and efficacy of parsaclisib in combination with investigator choice standard of care (SOC; rituximab [Treatment A], rituximab plus bendamustine [Treatment B], or ibrutinib [Treatment C]) in 50 patients with R/R B-cell lymphoma. The most common treatment-emergent adverse events included neutropenia (62...
April 10, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38597202/bruton-s-tyrosine-kinase-btk-inhibitors-for-the-treatment-of-primary-central-nervous-system-lymphoma-pcnsl-current-progress-and-latest-advances
#36
REVIEW
Lauren Schaff, Lakshmi Nayak, Christian Grommes
The incidence of primary central nervous system lymphoma (PCNSL) has steadily increased, particularly in elderly patients. Although highly responsive to first-line chemotherapy and radiotherapy, approximately 50% of patients relapse or become refractory within 1 year. Prognosis following relapse is dismal and no standard salvage therapy exists. Bruton's tyrosine kinase (BTK), a key regulator of the B-cell receptor (BCR) pathway, has emerged as a promising therapeutic target. The first BTK inhibitor ibrutinib has been evaluated in the relapsed/refractory PCNSL setting, with overall response rates of 51...
April 10, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38593054/the-prognostic-significance-of-genomic-complexity-in-patients-with-cll
#37
REVIEW
Ellinor Goergen, Othman Al-Sawaf
Chromosomal aberrations are a common feature of cancer and can fuel cancer progression and treatment resistance. In chronic lymphocytic leukemia (CLL), the presence of multiple chromosomal aberrations is commonly referred to as "genomic complexity" or "complex karyotype"- (CKT). In the context of chemo- and chemoimmunotherapy, genomic complexity is associated with poor response to treatment and short survival, while some targeted therapies are able to mitigate its adverse prognostic impact. This article reviews currently available data and literature on the role of genomic complexity in CLL...
April 9, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38587123/normal-and-malignant-cells-are-homogeneously-distributed-in-the-bone-marrow-of-children
#38
JOURNAL ARTICLE
Sharon Veenbergen, Romana Jugooa, Jeroen Te Marvelde, Andrica C H de Vries, Vincent H J van der Velden
No abstract text is available yet for this article.
April 8, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38581379/gammopathic-dermopathy-characterization-of-cutaneous-mgus
#39
JOURNAL ARTICLE
Emily R Gordon, Caroline Chen, Megan H Trager, Oluwaseyi Adeuyan, Brigit A Lapolla, Lauren M Fahmy, Celine M Schreidah, David A Wetter, Larisa J Geskin
Monoclonal Gammopathy of Undetermined Significance (MGUS) is a clonal plasma cell disorder that is considered preneoplastic, asymptomatic, and only requiring observation. However, MGUS may result in cutaneous complications, which are poorly understood, causing treatment delays and patient suffering. We present 30 patients with cutaneous findings associated with MGUS, characterizing clinical presentations, isoforms, treatments, and outcomes. These included: MGUS-associated 'rashes' (pruritic eczematous rashes), reactive and mucin-depositional conditions (pyoderma gangrenosum, scleromyxedema), M-protein-related deposition disorders (POEMS syndrome, Waldenstrom macroglobulinemia), and cutaneous lymphomas...
April 6, 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38567630/hospital-healthcare-resource-utilization-and-costs-for-chimeric-antigen-t-cell-therapy-and-autologous-hematopoietic-cell-transplant-in-patients-with-large-b-cell-lymphoma-in-the-united-states
#40
JOURNAL ARTICLE
Chendi Cui, Chaoling Feng, Ning Rosenthal, Sally W Wade, Laura Curry, Christine Fu, Gunjan L Shah
The efficacy of chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is well-established. This study, using the Premier PINC AI Healthcare Database, assessed hospital costs and healthcare resource utilization (HRU) between CAR T-cell therapy and autologous hematopoietic cell transplant (AHCT) for 733 LBCL patients from 01/01/2017-04/30/2021 (166 CAR T and 567 AHCT from 37 US hospital systems. CAR T-cell therapy had higher index costs but lower non-pharmacy costs, shorter hospital stays, lower ICU utilization than AHCT...
April 3, 2024: Leukemia & Lymphoma
journal
journal
30440
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.